Resources>Blog>VHH Antibodies

VHH Antibodies

Biointron 2024-01-20 Read time: 2 mins
VHH.jpg
Image credit: DOI: 10.1177/1535370219881129

Antibodies are essential tools in modern medicine and research, but not all antibodies are the same. VHH antibodies, also known as single-domain antibodies or nanobodies, are a type of antibody that offers several advantages over conventional antibodies. 

VHH antibodies are derived from the immune system of camelids, which produce antibodies that are much smaller than those produced by humans or mice. VHH antibodies consist of a single domain, or variable region, that is capable of binding to specific antigens. This makes them ideal for a wide range of applications, including diagnostic tests, therapeutics, and research tools. 

One key advantage of VHH antibodies is their small size. This allows them to penetrate tissues more effectively than larger antibodies, making them useful for targeting diseases that are difficult to reach with conventional therapies. Additionally, VHH antibodies are highly stable and can withstand harsh conditions, such as high temperatures or acidic environments, which makes them useful for a range of diagnostic and therapeutic applications. 

At Biointron, we specialize in the production of high-quality recombinant VHH antibodies for research and diagnostic purposes. Our team of experts uses state-of-the-art technologies to generate VHH antibodies that are highly specific and sensitive to their target antigens. Whether you need custom VHH antibody production or off-the-shelf options, we have the expertise to deliver the right solution for your needs. 

To learn more about our VHH antibody services, visit our website or contact us today. 

Subscribe to our Blog
Recommended Articles
New Companies Advancing Next-Gen Antibodies

A new generation of biotech companies is rapidly advancing the antibody landscap……

Apr 08, 2026
Roundup of Antibody Biotech Deals in March 2026

March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and a……

Apr 03, 2026
Why Antibody Programs Fail Early: Reducing Attrition in Drug Development

Clinical drug development remains associated with a high failure rate, primarily……

Mar 30, 2026
NextGen Biomed 2026 – London: Highlights and Event Recap

Read on for the key trends of the NextGen Biomed 2026 conference held in London ……

Mar 25, 2026

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.